Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Rituxan off-label

Executive Summary

Rituxan off-label use in intermediate and high-grade non-Hodgkin's lymphoma market reaches 60% market penetration at the end of the second quarter, Genentech Investor Relations Senior Director Susan Bentley says Sept. 25. Penetration in Rituximab's approved indication - low-grade, relapsed NHL - was more than 50%. "We're seeing Rituxan moving more to the front line, with approximately 50% of its use there now," Bentley added
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS038581

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel